Completed

Fluconazole vs Clotrimazole for Oropharyngeal Candidiasis in AIDS Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Clotrimazole

+ Fluconazole

Drug
Who is being recruted

Blood-Borne Infections+21

+ Urogenital Diseases

+ Genital Diseases

Over 13 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
See protocol details

Summary

Principal SponsorPfizer
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

This study focuses on comparing two treatments for oropharyngeal candidiasis, a condition commonly known as thrush, in patients who have AIDS. The two treatments are fluconazole, a single daily capsule, and clotrimazole troche, which is taken five times a day. The goal is to see which treatment works better, is safer, and is more easily tolerated by patients. This research is important because it aims to find the best treatment option for thrush in AIDS patients, which can improve their quality of life and help manage their condition more effectively.

NCT00002282
Principal SponsorPfizer
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 13 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesBacterial Infections and MycosesCandidiasisCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsStomatognathic DiseasesMouth DiseasesMycosesOpportunistic InfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeCandidiasis, OralHIV InfectionsAIDS-Related Opportunistic Infections

Criteria

2 inclusion criteria required to participate
Patients who have given informed consent in writing to their participation in the study
Patients with signs of oropharyngeal candidiasis, i.e., with typical white plaques
8 exclusion criteria prevent from participating
Excluded pending results of phase I studies to determine whether interaction between fluconazole and these agents occurs: Barbiturates, Phenytoin, Coumarin-type anticoagulants, Rifampin, Oral hypoglycemics, Cyclosporin
Known history of intolerance or allergy to imidazoles or triazoles, or the non-azole components of clotrimazole troches (dextrose, cellulose, povidone, magnesium stearate)
Life expectancy < 4 weeks
Moderate or severe liver disease defined by specified lab values
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 17 locations

Dr Robert Larsen

Los Angeles, United StatesOpen Dr Robert Larsen in Google Maps

Summitt Med Ctr / San Francisco Gen Hosp

Oakland, United States

Davies Med Ctr

San Francisco, United States

UCSF Hosp

San Francisco, United States
Completed17 Study Centers